Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.
Patients And Methods: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.
Results: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.
Conclusion: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.14725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nano-enabled repurposing of Benproperine phosphate enhances pancreatic Cancer chemotherapy through lethal autophagy arrest and immune activation.
J Control Release
September 2025
Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; MOE Joint International Research Laboratory of Pancreatic Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Gemcitabine-based chemotherapy remains a cornerstone in pancreatic cancer treatment, yet its efficacy is hindered by poor bioavailability and adaptive resistance mechanisms, such as autophagy. In this study, we developed a hyaluronic acid (HA) modified zeolitic imidazolate framework-8 (ZIF-8) drug-repurposing nanoplatform (HA/ZIF-8@BPP/Gem) against pancreatic cancer through the co-delivery of the antitussive benproperine phosphate (BPP) and gemcitabine (Gem). Using cell lines, patient-derived xenograft models, and orthotopic tumor models, we demonstrated that BPP and Gem, rapidly released from the nanoplatform in the acidic tumor microenvironment, exhibited synergistic cytotoxicity without causing significant biochemical abnormalities or organ toxicity.
View Article and Find Full Text PDFComparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG).
J Clin Med
August 2025
Department of Medical Oncology, School of Medicine, Hacettepe University, Ankara 06800, Turkey.
Adenocarcinoma arising from the ampulla of Vater is an extremely rare neoplasm, and there are limited data regarding frontline therapy for metastatic disease. We investigated the outcomes of first-line treatment with FOLFIRINOX by comparing it with other treatments in patients with advanced ampullary adenocarcinoma. We included 123 patients with advanced ampullary adenocarcinoma who were treated with frontline FOLFIRINOX ( = 32), fluorouracil (FU)-based chemotherapy ( = 20), and gemcitabine-based chemotherapy ( = 65) between August 2007 and January 2024 in this retrospective study.
View Article and Find Full Text PDFLiposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin.
Front Oncol
August 2025
Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Introduction: The combination of liposomal irinotecan with fluorouracil and leucovorin (Nal-IRI/FL) has shown efficacy in phase II trials for advanced biliary tract cancer (BTC) following gemcitabine-cisplatin (GP) therapy. However, its effectiveness and safety in real-world clinical settings have not been well established. This study aimed to assess the real-world outcomes of Nal-IRI/FL in BTC patients who experienced disease progression after gemcitabine-based treatment.
View Article and Find Full Text PDFBackground: Hepsin is a type 2 transmembrane serine protease (TTSP), primarily located on the cell membrane, which can degrade the extracellular matrix and modify connections between cells and the extracellular matrix. Given these features, hepsin is thought to play a role in cancer invasion and metastasis. While studied in various other cancers, hepsin's role in pancreatic cancer remains unexamined.
View Article and Find Full Text PDFThe Ideal Second-Line Treatment Options for Patients with Advanced Biliary Tract Cancer Refractory to Gemcitabine-Based First-Line Chemotherapy: A Result From Bayesian Network-Meta Analysis.
Asian Pac J Cancer Prev
August 2025
Division of Digestive Surgery, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Objective: To determine the most ideal second-line treatment for advanced biliary tract cancer, considering the response rate, survival, and drug adverse events.
Methods: This network meta analysis (NMA) was conducted in accordance with the PRISMA with NMA extension guidance. After formulation of PICO, comprehensive searches of literatures were done including all randomized controlled studies that reported the second-line treatment for advanced biliary tract cancers' subjects who have failed with first-line gemcitabine-based chemotherapy.